Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase Ib/II Study of YL201 Plus Atezolizumab in Advanced Solid Tumors
2025-523742-27-00Phase 2Authorised
- Sponsor
- MediLink Therapeutics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of YL201 in small cell lung cancer (SCLC) and Nonhematologic neoplasms, sponsored by MediLink Therapeutics. Primary endpoints: Part 1 Safety and DLTs, Part 2 Objective Response Rate and 1 more. Planned start Apr 2026; status: authorised.
02
Drugs
YL201
03
Conditions
small cell lung cancer (SCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523742-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523742-27-00.